US EditionSHAREHOLDER ALERT: Berger Montague Reminds Rocket Pharmaceuticals (NASDAQ: RCKT) Investors of Class Action Lawsuit Deadline
CRANBURY, NEW JERSEY, JUL 22 – The lawsuit alleges Rocket Pharmaceuticals hid serious safety updates including a fatal adverse event and an FDA clinical hold, causing stock to drop from $6.27 to $2.33, court filings show.
- A securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for alleged material misstatements and omissions, announced by Berger Montague PC, a law firm representing investors.
- Investors who purchased Rocket Pharmaceuticals stock from September 17, 2024, to May 26, 2025, may be eligible for compensation.
- The lawsuit alleges that Rocket Pharmaceuticals did not disclose important safety updates regarding its RP-A501 clinical trial before a patient death and subsequent FDA clinical hold.
- Following the announcement of the clinical hold and patient death on May 28, 2025, Rocket Pharmaceuticals' shares significantly dropped from $6.27 to $2.33.
Insights by Ground AI
Does this summary seem wrong?
50 Articles
50 Articles
The Berkshire Eagle+47 Reposted by 47 other sources
SHAREHOLDER ALERT: Berger Montague Reminds Rocket Pharmaceuticals (NASDAQ: RCKT) Investors of Class Action Lawsuit Deadline
PHILADELPHIA, July 21, 2025 /PRNewswire/ -- Berger Montague PC, a leading Philadelphia-based law firm representing investors, announces that a securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket Pharmaceuticals" or the "Company") on behalf of…
ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Rocket Pharmaceuticals, Inc. Investors of Upcoming Deadline...
Coverage Details
Total News Sources50
Leaning Left5Leaning Right7Center13Last UpdatedBias Distribution52% Center
Bias Distribution
- 52% of the sources are Center
52% Center
L 20%
C 52%
R 28%
Factuality
To view factuality data please Upgrade to Premium
